iMDx posts Q2 loss as FDA review of GraftAssureDx continues
Go back to iMDx posts Q2 loss as FDA review of GraftAssureDx continues| BIO-RAD LABORATORIES (NYSE: BIO) | Delayed: 380.96 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $380.96 | 52 Week High | $174.02 | |||
| Open | $380.96 | 52 Week Low | $122.03 | |||
| Day High | $380.96 | P/E | 123.29 | |||
| Day Low | $380.96 | EPS | $3.09 | |||
| Volume | 934 | |||||
| (NASDAQ: IMDX) | Delayed: 3.84 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.84 | 52 Week High | $ | |||
| Open | $3.84 | 52 Week Low | $ | |||
| Day High | $3.84 | P/E | N/A | |||
| Day Low | $3.84 | EPS | $ | |||
| Volume | 894 | |||||

